enGene Holdings Inc. Common Stock (NASDAQ: ENGN) — Healthcare · Share Price, Chart & Market Data
About: enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.99 (-1.84%)
ENGNenGene Holdings Inc. Common Stock
Loading watchlist status…
Trade ENGN now
enGene Holdings Inc. Common Stock share price
ENGN price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 9:01 am GMT+0
ENGN price performance
-6.11%
5D
25.432%
1M
-9.783%
YTD
83.459%
1Y
ENGN price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 9:01 am GMT+0
ENGN details
ENGN Market Signals